Ad
No verificado

AdvanCell

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud
23/10/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Eventos
Ferias y Congresos
Industria
AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data
1.00
21/07/2026
Eventos
Ferias y Congresos
Ciencia
Medicina nuclear
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026
1.00
15/07/2026
Ciencia
Medicina nuclear
Hardware
Farmacéutica
Tecnología de la información
Oncología
Técnica
Material médico sanitario
Medicina - Varios
Biotecnología
Higiene alimentaria
Salud
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure
1.00
22/06/2026
Oncología
Salud
Medicina - Varios
Medicina nuclear
Farmacéutica
Biotecnología
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy
1.00
08/06/2026
Mercado laboral
Biotecnología
Salud
Medicina nuclear
Farmacéutica
Oncología
Ciencia
Ir de compras
Medicina - Varios
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform
1.00
24/02/2026
Eventos
Industria
Ciencia
Medicina - Varios
Biotecnología
Medicina nuclear
Farmacéutica
Ir de compras
Salud
Oncología
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
1.00
08/12/2025
Industria
Tercera edad
Medicina - Varios
Biotecnología
Medicina nuclear
Salud
Ir de compras
Farmacéutica
Oncología
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0